Skip to main content
SpringerLink
Log in
Book cover

Verhandlungen der Deutschen Gesellschaft für innere Medizin pp 113–162Cite as

Klinische Pharmakologie in der inneren Medizin

  • Conference paper

  • 24 Accesses

Part of the book series: Verhandlungen der Deutschen Gesellschaft für innere Medizin ((VDGINNERE,volume 89))

Zusammenfassung

Zunächst zwei Binsenwahrheiten:

  1. 1.

    Es gibt wesentlich mehr Arzneimittel als notwendig sind.

  2. 2.

    Der Arzt, unabhangig davon, ob Allgemeinarzt oder Facharzt, verschreibt nur eine begrenzte Zahl von Medikamenten, die in den meisten Fällen unter 100 liegt und selten über 250 ansteigt.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Feely J, Wormsley KG (1983) H2-receptor antagonists — cimetidine and ranitidine. Br Med J 286:695–697

    Article  CAS  Google Scholar 

  • Friebel H (1981) Arzneimittelverbrauch. Dtsch Apoth Z 122:815–818

    Google Scholar 

  • Gross F (1981) Drug utilization — Theory and practice. The present situation in the Federal Republic of Germany. Eur J Clin Pharmacol 19:387–394

    Article  PubMed  CAS  Google Scholar 

  • Lunde PKM (1976) Differences in national drug prescribing-patterns. In: Clinical pharmacological evaluation in drug control. WHO, Regional Office for Europe, Copenhagen, pp 19–47

    Google Scholar 

  • Lunde PKM, Baksaas I, Halse M, Halvorsen T, Stromnes B, øydvin K (1979) The methodology of drug utilisation studies. In: Bergman U, Grimsson A, Wahba AHW, Westerholm B (eds) Studies in drug utilisation — Methods and applications. WHO Regional Publications, European Series No. 8, Copenhagen, pp 17–28

    Google Scholar 

  • Schüren KP, Rietbrock (1982) Digitalisbehandlung in Deutschland. Dtsch Med Wochenschr 107:1935–1938

    PubMed  Google Scholar 

Literatur

  1. Ash ASF, Schild HO (1966) Receptors mediating some action of histamine. Br J Pharmacol Chemother 27: 427–439

    PubMed  CAS  Google Scholar 

  2. Black JW, Duncan WAM, Durant GJ (1972) Definition and antagonism of histamine H2-receptors. Nature 236: 385–390

    Article  PubMed  CAS  Google Scholar 

  3. Bardhan KD (1982) The short- and medium-term treatment of duodenal ulcer with cimetidine. In: Bianchi Porro G, Bardhan KD (eds) Cortina international verona. Raven Press, pp 85–106

    Google Scholar 

  4. Gugler R, Rohner H-G, Somogyi A (1982) Therapieversager unter Cimetidin beim Ulcus duodeni. Dtsch Med Wochenschr 107: 1054–1057

    Article  PubMed  CAS  Google Scholar 

  5. Somogyi AA, Rohner H-G, Gugler R (1980) Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet 5: 84–94

    Article  PubMed  CAS  Google Scholar 

  6. Gugler R, Fuchs G, Dieckmann M, Somogyi A (1981) Cimetidine plasma concentration-response relationships. Clin Pharmacol Ther 29: 744–748

    Article  PubMed  CAS  Google Scholar 

  7. Heagerty AM, Donovan MA, Castleden CM, Pohl JF, Patel L, Hedges A (1981) Influence of cimetidine on pharmacokinetics of propranolol. Br Med J 282:1917–1919

    Article  CAS  Google Scholar 

  8. Feely J, Wilkinson GR, Wood AJJ (1981) Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304: 692–695

    Article  PubMed  CAS  Google Scholar 

  9. Somogyi A, Gugler R (1982) Drug interactions with cimetidine. Clin Pharmacokinet 7: 23–41

    Article  PubMed  CAS  Google Scholar 

  10. Rohner H-G, Blorner A, Echterhoff H-M, Gugler R (1983) Operationshäufigkeit beim Magen- und Duodenalulcus 5 Jahre vor und nach Einführung von Cimetidin. Verh Dtsch Ges Inn Med 89 (im Druck)

    Google Scholar 

Literatur

  1. Aellig WH (1978) Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers. Eur J Clin Pharmacol 14:167–169

    Article  PubMed  CAS  Google Scholar 

  2. Robinson BF (1967) Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris. Circulation 35: 1073–1083

    PubMed  CAS  Google Scholar 

  3. Prichard BNC, Gillam PMS (1971) Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise. Br Heart J 33: 473–480

    Article  Google Scholar 

  4. Prichard BNC (1964) Hypotensive action of pronethalol. Br Med J 1: 1227–1228

    Article  PubMed  CAS  Google Scholar 

  5. Prichard BNC, Gillam PMS (1969) Treatment of hypertension with propranolol. Br Med J 1: 7–16

    Article  PubMed  CAS  Google Scholar 

  6. Louis WJ, Rand MJ, McNeil JJ, Drummer O, Jarrott B (1979) Clinical pharmacology of adrenergic-blocking drugs. Cardiology (Suppl 1) 64: 96–104

    Article  PubMed  Google Scholar 

  7. Turner P (1974) Beta-adrenergic receptor blocking drugs in hyperthyroidism. Drugs 7: 48–54

    Article  PubMed  CAS  Google Scholar 

  8. Gilligan BS, Veale JL, Wodak J (1972) Propranolol in the treatment of tremor. Med J Austr 1: 320–322

    CAS  Google Scholar 

  9. Weber RB, Reinmuth OM (1972) The treatment of migraine with propranolol. Neurology 22: 366–369

    PubMed  CAS  Google Scholar 

  10. Phillips CI, Howitt G, Rowlands DJ (1967) Propranolol as ocular hypotensive agent. Br J Ophthalmol 51: 222–226

    Google Scholar 

  11. Gloor B (1980) Lokale Glaukomtherapie. Medikamente mit Wirkung am adrenergen System. Pharma-Kritik 20:77–80

    Google Scholar 

  12. Rode P, Heinrich F, Voegt H (1971) Auswirkungen der Beta-Rezeptorenblockade auf Systolendauer und Temporaliskurve unter Orthostasebedingungen. Med Welt 22:1733–1737

    Google Scholar 

  13. Miller AJ, Cohen HC, Glick G (1974) Propranolol in the treatment of orthostatic tachycardia associated with orthostatic hypotension. Am Heart J 88: 493–495

    Article  PubMed  CAS  Google Scholar 

  14. Man in’t Veld AJ, Boomsma F, Schalekamp MADH (1982) Effects of beta-adrenoceptor agonists and antagonists in patients with peripheral autonomic neuropathy. Br J Clin Pharmacol 13: 367S–374S

    PubMed  Google Scholar 

  15. Lorimer AR, Dunn FG, Jones JV, Lawrie TDV (1976) Beta-adrenoceptor blockade in hypertension. Am J Med 60:877–885

    Article  PubMed  CAS  Google Scholar 

  16. Heidbreder E, Ziegler A, Heidland A (1982) Verhindern sympathikolytische Antihypertensiva den Blutdruckanstieg bei mentalem Streß. Herz-Kreislauf 14:135–141

    Google Scholar 

  17. Trap-Jensen J, Carlsen JE, Harding OJ, Svendsen TL, Tangø M, Christensen NJ (1982) Beta-adrenoceptor blockade and psychic stress in man. A comparison of the acute effects of labetalol, metoprolol, pindolol and propranolol on plasma levels of adrenaline and noradrenaline. Br J Clin Pharmacol 13: 391S–395S

    PubMed  CAS  Google Scholar 

  18. Brisse B, Tetsch P, Jacobs W, Bender F (1982) Beta-adrenoceptor blockade in stress due to oral surgery. Br J Clin Pharmacol 13: 421S–427S

    PubMed  CAS  Google Scholar 

  19. Tyrer PJ, Lader MH (1974) Physiological response to propranolol and diazepam in chronic anxiety. Br J Clin Pharmacol 1:387–390

    Google Scholar 

  20. Prichard BNC (1964) Some cardiovascular actions of adrenergic beta-receptor blocking drugs in man. Pharmacologist 6:166

    Google Scholar 

  21. A multicentre International Study (1975) Improvement in prognosis of myocardial infarction by long-term beta-adrenoceptor blockade using practolol. Br Med J 3:735–740

    Article  Google Scholar 

  22. Vedin A, Wilhelmsson C, Werkö L (1975) Chronic alprenolol treatment of patients with acute myocardial infarction after discharge from hospital. Effects on mortality and morbidity. Acta Med Scand [Suppl] 575: 7–41

    Google Scholar 

  23. Lambert DMD (1974) Hypertension and myocardial infarction. Br Med J 3: 685–686

    Article  PubMed  CAS  Google Scholar 

  24. The Norwegian Multicentre Study Group (1981) Timolol-induced reduction in mortality and re-infarction in patients surviving acute myocardial infarction. N Engl Med J 304:801–807

    Article  Google Scholar 

  25. Beta-Blocker Heart Attack Trial Research Group (1982) A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 247:1707–1714

    Article  Google Scholar 

  26. Lewis JA (1982) Beta-blockade after myocardial infarction — a statistical view. Br J Clin Pharmacol 14:15S–21S

    PubMed  Google Scholar 

  27. Staessen J, Bulpitt C, Cattaert A, Fagard R, Vanhees L, Amery A (1982) Secondary prevention with beta-adrenoceptor blockers in post-myocardial infarction patients. Am Heart J 104:1395–1399

    Article  PubMed  CAS  Google Scholar 

  28. Gross F (1982) Läßt sich der plötzliche Herztod verhüten? Münch Med Wochenschr 124: 27–31

    CAS  Google Scholar 

  29. Chamberlain DA (1983) Beta-adrenoceptor antagonists after myocardial infarction — where are we now? Br Heart J 49:105–110

    Article  PubMed  CAS  Google Scholar 

  30. Robertson RM, Wood AJJ, Vaughn WK, Robertson D (1982) Exacerbation of vasotonic angina pectoris by propranolol. Circulation 65: 281–285

    Article  PubMed  CAS  Google Scholar 

  31. Aellig WH (1982) Pindolol — a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations. Br J Clin Pharmacol 13:187S–192S

    PubMed  CAS  Google Scholar 

  32. Aellig WH (1983) Clinical pharmacological investigations of the partial agonist activity of beta-adrenoceptor antagonists. Hospital Formulary (in press)

    Google Scholar 

  33. Aellig WH (1976) Beta-adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol 3: 251–257

    PubMed  CAS  Google Scholar 

  34. Jennings G, Bobik A, Korner P (1981) Influence of intrinsic sympathomimetic activity of beta-adrenoceptor blockers on the heart rate and blood pressure responses to graded exercise. Br J Clin Pharmacol 12: 355–362

    PubMed  CAS  Google Scholar 

  35. Meier J (1980) Pharmacokinetic comparison of pindolol with other beta-adrenoceptor blocking agents. Am Heart J 104: 364–373

    Article  Google Scholar 

  36. Ruffin RE, McIntyre ELM, Latimer KM, Ward HE, Crockett AJ, Alpers JH (1982) Assessment of beta-adrenoceptor antagonists in asthmatic patients. Br J Clin Pharmacol 13: 325S–335S

    PubMed  CAS  Google Scholar 

  37. Dorow P (1982) Influence of intrinsic sympathomimetic activity (ISA) during beta-adrenoceptor blockade in asthmatics. Br J Clin Pharmacol 13: 321S–323S

    PubMed  CAS  Google Scholar 

  38. Waal-Manning HJ (1979) Can beta-blockers be used in diabetic patients? Drugs 17:157–160

    Article  PubMed  CAS  Google Scholar 

  39. Schluter KJ, Aellig WH, Petersen KG, Rieband H-CH, Wehrli A, Kerp L (1982) The influence of beta-adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo-and hyperglycaemia. Br J Clin Pharmacol 13: 407S–417S

    PubMed  CAS  Google Scholar 

  40. Cohn JN, Mehta J, Francis GS (1982) A review of the haemodynamic effects of labetalol in man. Br J Clin Pharmacol 13:19SS–26S

    Google Scholar 

  41. Man in’t Veld AJ, Schalekamp MADH (1982) How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. Br J Clin Pharmacol 13:245S–257S

    Google Scholar 

Literatur

  1. Batchelor JR, Welsh KI, Tinoco RM, Dollery CT, Hughes GRV, Bernstein R, Ryan P, Naish PF, Aber GM, Bing RF, Russell GI (1980) Hydralazine-induced systemic Lupus erythematosus: Influence of HLA-DR and sex on susceptibility. Lancet 1: 1107–1109

    Article  PubMed  CAS  Google Scholar 

  2. Eichelbaum M (1982) Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clin Pharmacokinet 7:1–22

    Article  PubMed  CAS  Google Scholar 

  3. Eichelbaum M (1983) Genetische Polymorphismen des oxidativen Arzneimittelstoffwechsels. Therapeutische und toxikologische Implikationen. Internist 24:117–127

    PubMed  CAS  Google Scholar 

  4. Goedde HW (1974) Pharmakogenetik: Variabilität von Arzneimittelwirkung und Stoffwechselreaktionen. Internist 15:27–39

    PubMed  CAS  Google Scholar 

  5. Roots I (1982) Genetische Ursachen für die Variabilität der Wirkungen und Nebenwirkungen von Arzneimitteln. Internist 23: 601–609

    PubMed  CAS  Google Scholar 

Literatur

  • Meyer BR (1982) Benzodiazepines in the elderly. Med Clin North Am 66: 1017–1035

    PubMed  CAS  Google Scholar 

  • Schöpf J (1983) Withdrawal phenomena after long-term administration of benzodiazepines — A review of recent investigations. Pharmacopsychiatria 16: 1–8

    Article  PubMed  Google Scholar 

Literatur

  • Bötiger LE, Westerholm B (1973) Drug-induced blood dyscrasias in Sweden. Br Med J 3: 339–343

    Article  Google Scholar 

  • Eisenbrand G, Schmähl D (1981) Nitrosation of drugs. In: Breimer DD, Speiser P (eds) Topics in pharmaceutical sciences. Elsevier/North Holland Biomedical Press

    Google Scholar 

  • Habs M, Eisenbrand G, Habs H, Schmähl D (1982) No evidence of carcinogeniCity of N-nitrosocimetidine in rats. Hepatogastroenterol 29: 265–266

    CAS  Google Scholar 

  • Halpin TJ, Holtzhauer FJ, Campbell RJ, Hall LJ, Correa-Villasenor A, Lanese R, Rice J, Hurwitz ES (1982) Reye’s syndrome and medication use. JAMA 248: 687–691

    Article  PubMed  CAS  Google Scholar 

  • Heimpel H, Abt C (1979) Medikamente und akute Agranulozytose. Dtsch Med Wochenschr. 104:731–736

    Article  PubMed  CAS  Google Scholar 

  • Lenz W (1965) Epidemiology of congenetal malformations. Ann NY Acad Sci 123:228–236

    Article  PubMed  CAS  Google Scholar 

  • Lewis JH, Zimmermann HJ, Carrett CT, Rosenberg E (1982) Valproate-induced hepatic steatogenesis in rats. Hepatology 2: 870–873

    Article  PubMed  CAS  Google Scholar 

  • Linnemann CC, Shea L, Kauffman CA, Schiff GM, Partin JC, Schubert WK (1974) Association of Reye’s syndrome with viral infection. Lancet 2/27:179–182

    Article  PubMed  Google Scholar 

  • Nieweg HO, Bouma HGD, De Vries K, Jansz A (1963) Haematological side-effects of some anti-rheumatic drugs. Ann Rheum Dis 22: 440–443

    Article  PubMed  CAS  Google Scholar 

  • Partin JC, Schubert WK, Partin JS (1971) Mitochondrial ultrastructure in Reye’s syndrome (encephalopathy and fatty degeneration of the viscera). N Engl J Med 285: 1339–1343

    Article  PubMed  CAS  Google Scholar 

  • Report from the International Agranulocytosis and Aplastic Anemia Study (1983) The design of a study of the drug etiology of agranulocytosis and aplastic anemia. Eur J Clin Pharmacol (in press)

    Google Scholar 

  • Reye’s RDK, Morgan G, Barai J (1963) Encephalopathy and fatty degeneration of the viscera — a disease entity in childhood. Lancet 2: 749–752

    Google Scholar 

  • Reye’s Syndrome — Epidemiological Considerations (1982) Lancet 1: 941–943

    Google Scholar 

  • Starko KM, Ray CG, Dominguez LB, Stromberg WL, Woodall DF (1980) Reye’s syndrome and salicylate use. Pediatrics 66: 859–864

    PubMed  CAS  Google Scholar 

  • Stockbrugger RW, Cotton PB, Eugenides N, Bartholomew BA, Hill MJ, Walters CL (1982) Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment. Gut 23:1048–1054

    Article  PubMed  CAS  Google Scholar 

  • Tang TT, Siegesmund KA, Sedmak GV, Casper JT, Varma RR, McCreadie SR (1975) Reye syndrome: A correlated electron-microscopic, viral, and biochemical observation. JAMA 232:1339–1346

    Article  PubMed  CAS  Google Scholar 

  • Waldman RJ, Hall WN, McGree H, Van Amburg G (1982) Aspirin as a risk factor in Reye’s syndrome. JAMA 247:3089–3094

    Article  PubMed  CAS  Google Scholar 

  • Zimmerman HJ, Ishak KG (1982) Valproate-induced hepatic injury:. Analyses of 23 fetal cases. Hepatology 2:591–597

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inst. für klin. Pharmakologie, Inselspital der Univ. Bern, Schweiz

    R. Preisig

  2. Pharmakolog. Inst. der Univ. Heidelberg, Deutschland

    F. Gross

  3. Med. Klinik der Univ. Bonn, Deutschland

    R. Gugler

  4. Abt. Experimentelle Therapie, Sandoz AG, Basel, Schweiz

    W. H. Aellig

  5. Med. Klinik der Univ. Bonn, Deutschland

    M. Eichelbaum

  6. Med. Univ.-Klinik Essen, Deutschland

    E. E. Ohnhaus

  7. Psychiatr. Univ.-Klinik Zurich, Schweiz

    J. Angst

  8. Inst. für klin. Pharmakologie, Berlin, Deutschland

    H. Kewitz, T. Lindner & M. Nitz

Authors
  1. R. Preisig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Gugler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. H. Aellig
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Eichelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. E. Ohnhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Angst
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Kewitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T. Lindner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Nitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kliniken der Landeshauptstadt Wiesbaden, Wiesbaden, D-6200, Deutschland

    Bernhard Schlegel

Rights and permissions

Reprints and permissions

Copyright information

© 1983 J. F. Bergmann Verlag, München

About this paper

Cite this paper

Preisig, R. et al. (1983). Klinische Pharmakologie in der inneren Medizin. In: Schlegel, B. (eds) Verhandlungen der Deutschen Gesellschaft für innere Medizin. Verhandlungen der Deutschen Gesellschaft für innere Medizin, vol 89. J.F. Bergmann-Verlag. https://doi.org/10.1007/978-3-642-85456-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85456-9_3

  • Publisher Name: J.F. Bergmann-Verlag

  • Print ISBN: 978-3-8070-0335-1

  • Online ISBN: 978-3-642-85456-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation